NO843726L - 2,5-disubstituerte-4(3h)-pyrimidoner med histamin h2-reseptor antagonistvirkning - Google Patents

2,5-disubstituerte-4(3h)-pyrimidoner med histamin h2-reseptor antagonistvirkning

Info

Publication number
NO843726L
NO843726L NO843726A NO843726A NO843726L NO 843726 L NO843726 L NO 843726L NO 843726 A NO843726 A NO 843726A NO 843726 A NO843726 A NO 843726A NO 843726 L NO843726 L NO 843726L
Authority
NO
Norway
Prior art keywords
pyrimidones
histamine
disubstituted
receptor antagonist
antagonist effect
Prior art date
Application number
NO843726A
Other languages
English (en)
Other versions
NO161561B (no
NO161561C (no
Inventor
Aldo A Algieri
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NO843726L publication Critical patent/NO843726L/no
Priority to NO874992A priority Critical patent/NO173235C/no
Publication of NO161561B publication Critical patent/NO161561B/no
Publication of NO161561C publication Critical patent/NO161561C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO843726A 1983-09-21 1984-09-19 Fremgangsmaate til fremstilling av 4(3h)-pyrimidoner. NO161561C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO874992A NO173235C (no) 1983-09-21 1987-11-30 Analogifremgangsmaate til fremstilling av 4(3h)pyrimidoner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/534,426 US4772704A (en) 1983-09-21 1983-09-21 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity

Publications (3)

Publication Number Publication Date
NO843726L true NO843726L (no) 1985-03-22
NO161561B NO161561B (no) 1989-05-22
NO161561C NO161561C (no) 1989-08-30

Family

ID=24129972

Family Applications (1)

Application Number Title Priority Date Filing Date
NO843726A NO161561C (no) 1983-09-21 1984-09-19 Fremgangsmaate til fremstilling av 4(3h)-pyrimidoner.

Country Status (36)

Country Link
US (1) US4772704A (no)
JP (1) JPH0643310B2 (no)
KR (1) KR900001198B1 (no)
AR (2) AR242385A1 (no)
AT (1) AT387965B (no)
AU (1) AU583479B2 (no)
BE (1) BE900652A (no)
CA (1) CA1260463A (no)
CH (1) CH665840A5 (no)
CS (1) CS249147B2 (no)
CY (1) CY1561A (no)
DD (1) DD226881A5 (no)
DE (1) DE3434578A1 (no)
DK (1) DK162987C (no)
ES (4) ES8607253A1 (no)
FI (1) FI83868C (no)
FR (1) FR2552082B1 (no)
GB (1) GB2146994B (no)
GR (1) GR80439B (no)
HK (1) HK73790A (no)
HU (1) HU193227B (no)
IE (1) IE58083B1 (no)
IL (1) IL72990A (no)
IT (1) IT1176739B (no)
LU (1) LU85550A1 (no)
NL (1) NL8402898A (no)
NO (1) NO161561C (no)
NZ (1) NZ209572A (no)
OA (1) OA07820A (no)
PT (1) PT79256B (no)
SE (1) SE463209B (no)
SG (1) SG60890G (no)
YU (1) YU45205B (no)
ZA (1) ZA847345B (no)
ZM (1) ZM4984A1 (no)
ZW (1) ZW16084A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
WO2022034121A1 (en) 2020-08-11 2022-02-17 Université De Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151188B (no) * 1978-02-13 1983-03-05 Smith Kline French Lab
ES477520A1 (es) * 1978-02-25 1979-06-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevas penicilinas.
PH16240A (en) * 1978-04-11 1983-08-11 Smith Kline French Lab Process for making histamine antagonist
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4521418A (en) * 1979-02-21 1985-06-04 Smith Kline & French Laboratories Limited Guanidinothiazolyl derivatives
AU531142B2 (en) * 1979-04-04 1983-08-11 Smith Kline & French Laboratories Limited 2 amino- pyimindones
CA1140129A (en) * 1979-08-21 1983-01-25 Ronald J. King 4-pyrimidone derivatives
ZW21281A1 (en) * 1980-10-01 1981-11-18 Smith Kline French Lab Amine derivatives
US4352933A (en) * 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
NZ202797A (en) * 1981-12-28 1985-08-30 Lilly Co Eli Pyrimidine derivatives and pharmaceutical compositions
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
GB8320505D0 (en) * 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
CA1275097A (en) * 1984-10-02 1990-10-09 Fujio Nohara Pyridyloxy derivatives

Also Published As

Publication number Publication date
IT8422744A1 (it) 1986-03-20
DK450484D0 (da) 1984-09-20
SE8404729L (sv) 1985-03-22
FR2552082A1 (fr) 1985-03-22
DK162987B (da) 1992-01-06
IL72990A (en) 1990-07-12
HUT35259A (en) 1985-06-28
CA1260463A (en) 1989-09-26
HU193227B (en) 1987-08-28
FR2552082B1 (fr) 1987-02-20
KR850002259A (ko) 1985-05-10
ES8702897A1 (es) 1987-01-16
GB2146994A (en) 1985-05-01
SG60890G (en) 1990-09-07
ES544213A0 (es) 1987-04-01
AT387965B (de) 1989-04-10
IE842406L (en) 1985-03-21
AR242789A1 (es) 1993-05-31
YU45205B (en) 1992-05-28
AU3335184A (en) 1985-03-28
CS249147B2 (en) 1987-03-12
ES8704465A1 (es) 1987-04-01
IT8422744A0 (it) 1984-09-20
ES8607253A1 (es) 1986-05-16
IT1176739B (it) 1987-08-18
HK73790A (en) 1990-09-28
NL8402898A (nl) 1985-04-16
YU161384A (en) 1987-12-31
LU85550A1 (fr) 1985-06-04
DD226881A5 (de) 1985-09-04
DK162987C (da) 1992-06-01
JPH0643310B2 (ja) 1994-06-08
KR900001198B1 (ko) 1990-02-28
US4772704A (en) 1988-09-20
ZA847345B (en) 1985-06-26
NO161561B (no) 1989-05-22
NZ209572A (en) 1988-05-30
CH665840A5 (de) 1988-06-15
FI83868B (fi) 1991-05-31
BE900652A (fr) 1985-03-21
PT79256B (en) 1986-11-20
IE58083B1 (en) 1993-06-30
FI843643L (fi) 1985-03-22
ZM4984A1 (en) 1985-05-21
SE8404729D0 (sv) 1984-09-20
PT79256A (en) 1984-10-01
FI843643A0 (fi) 1984-09-18
GR80439B (en) 1985-01-22
ES551500A0 (es) 1987-03-16
ATA300984A (de) 1988-09-15
ES536054A0 (es) 1986-05-16
CY1561A (en) 1991-03-22
ZW16084A1 (en) 1985-01-16
ES551501A0 (es) 1987-01-16
AR242385A1 (es) 1993-03-31
SE463209B (sv) 1990-10-22
OA07820A (fr) 1986-11-20
GB8423863D0 (en) 1984-10-24
JPS6087271A (ja) 1985-05-16
DE3434578A1 (de) 1985-04-11
NO161561C (no) 1989-08-30
AU583479B2 (en) 1989-05-04
GB2146994B (en) 1987-09-03
FI83868C (fi) 1991-09-10
ES8704155A1 (es) 1987-03-16
DK450484A (da) 1985-03-22

Similar Documents

Publication Publication Date Title
GB2135311B (en) Novel xanthine-type adenosine receptor antagonists
DK435681A (da) Pyrimidonderivater med histamin h2-antagonistvirkning
IT8422841A0 (it) Testa per doccia.
FI922143A7 (fi) Muscarinreceptorantagonister.
FI941178A7 (fi) 5-HT4-reseptoriantagonisteja
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
FI922344L (fi) Muscarinreceptorantagonister.
DE3574665D1 (de) Glutamatrezeptorshemmstoff.
ATE57187T1 (de) Vincaleukoblastin-derivate.
FI843221A7 (fi) Lh/rh antagonister.
DK298180A (da) Histamin h2-antagonister
DE3475713D1 (de) 3, 3", 4" -tri-o-acylspiramycin i
FI894675A7 (fi) Muskarinreceptorantagonister.
ZA783141B (en) Histamine h2 receptor antagonists
FI845095A7 (fi) Aminoimidatsolonijohdannaiset histamiini-H2-antagonisteina.
NO831100L (no) Substituerte 3,4-diamino-1,2,5-tiadiazoler med histamin h2-reseptorantagonistvirkning
ZA894097B (en) Alpha-adrenergic receptor antagonists
AU583479B2 (en) 2,5-Disubstituted-4(3H)-pyrimidones having histamine H 2-receptor antagonist activity
FR2566406B1 (fr) 3,4-diamino-1,2,5-thiadiazoles substitues presentant une activite antagoniste du recepteur h2 de l'histamine
DK325784A (da) Cytosinderivater, som er histamin h2-antagonister
FI922346A7 (fi) Muscarinreceptorantagonister.
DK624284D0 (da) Aminoimidazolinonderivater som histamin h2-antagonister
DE69004827D1 (de) Alpha-adrenergene Rezeptor-Antagonisten.
FI905922A7 (fi) a-adrenergisen reseptorin antagonistit
IE881220L (en) 5-ht3 receptor antagonists